Duan Xiaohua, Lacko Lauretta A, Chen Shuibing
Department of Surgery, Weill Cornell Medicine, New York, NY, United States.
Front Chem. 2022 Oct 5;10:963701. doi: 10.3389/fchem.2022.963701. eCollection 2022.
Coronavirus disease (COVID-19), which is caused by SARS-CoV-2, is the biggest challenge to the global public health and economy in recent years. Until now, only limited therapeutic regimens have been available for COVID-19 patients, sparking unprecedented efforts to study coronavirus biology. The genome of SARS-CoV-2 encodes 16 non-structural, four structural, and nine accessory proteins, which mediate the viral life cycle, including viral entry, RNA replication and transcription, virion assembly and release. These processes depend on the interactions between viral polypeptides and host proteins, both of which could be potential therapeutic targets for COVID-19. Here, we will discuss the potential medicinal value of essential proteins of SARS-CoV-2 and key host factors. We summarize the most updated therapeutic interventions for COVID-19 patients, including those approved clinically or in clinical trials.
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的冠状病毒病（COVID-19）是近年来全球公共卫生和经济面临的最大挑战。到目前为止，COVID-19患者可用的治疗方案有限，这引发了对冠状病毒生物学进行前所未有的研究努力。SARS-CoV-2的基因组编码16种非结构蛋白、4种结构蛋白和9种辅助蛋白，这些蛋白介导病毒的生命周期，包括病毒进入、RNA复制和转录、病毒粒子组装和释放。这些过程依赖于病毒多肽与宿主蛋白之间的相互作用，二者都可能是COVID-19的潜在治疗靶点。在此，我们将讨论SARS-CoV-2必需蛋白和关键宿主因子的潜在药用价值。我们总结了针对COVID-19患者的最新治疗干预措施，包括那些已获临床批准或正在进行临床试验的措施。
